Allergy Therapeutics plc Phase III PQ Grass trial now planned
Allergy Therapeutics plc (LON: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the outcome of successful discussions with the Paul Ehrlich Institut in Germany and the